Validation and normative data for the BAC app in Spanish-speaking individuals with psychosis and healthy controls
- PMID: 40785579
- PMCID: PMC12438988
- DOI: 10.1192/j.eurpsy.2025.10076
Validation and normative data for the BAC app in Spanish-speaking individuals with psychosis and healthy controls
Abstract
Background: Cognitive impairment is central to psychosis and strongly linked to functional outcomes. The Brief Assessment of Cognition (BAC) app is a tablet-based, automated tool for assessing key cognitive domains but has not been validated in Spanish-speaking populations or across illness stages.
Methods: A total of 402 participants (117 with first-episode psychosis [FEP], 125 with schizophrenia, and 160 controls) completed the BAC app along with clinical and functional assessments. We evaluated internal consistency, group differences, convergent and discriminant validity, and the effects of sex, age, and education. Normative percentiles were derived from controls.
Results: The BAC app showed good internal consistency across groups (α = 0.76-0.87) and effectively differentiated individuals with psychosis from controls (area under the curve [AUC] = 0.862), with performance declining from controls to FEP to schizophrenia. Discrimination between FEP and schizophrenia was limited (AUC = 0.649). BAC App correlated positively with estimated intelligence quotient and functional capacity, and negatively with symptom severity, particularly in FEP. Performance varied by age, sex, and education, supporting the need for stratified normative data.
Conclusions: The BAC app showed strong reliability and validity for cognitive assessment in Spanish-speaking individuals with psychosis. Its brevity, automated scoring, and normative data support its clinical and research applications for cognitive screening, monitoring, and treatment evaluation.
Keywords: BAC app; cognitive assessment; first-episode psychosis; normative data; schizophrenia; validation study.
Conflict of interest statement
RR-J has served as a consultant, has given lectures, or has received funding from Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda, Exeltis, Casen-Recordati, Angelini, and Rovi. These relationships are unrelated to the present work.
Figures


References
-
- Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: A meta-analytic review. Neuropsychology. 2009;23:315–36. - PubMed
-
- Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–13. - PubMed
-
- Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68:283–97. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical